Cardiovascular Panel

The Cardio Panel provides genetic results for

CYP2C19 Platelet inhibitor metabolism
CYP2D6 Beta Blocker Metabolism. It metabolizes 25% of all prescribed drugs.
VKORC1 and 2C9 Warfarin Response
Factor V Leiden Inherited Thrombophilia
Factor 2 Prothrombin deficiency
MTHFR A decrease in the function or amount of MTHFR causes increased blood levels of homocysteine. Increased homocysteine blood concentrations are associated with an increased risk for cardiovascular disease including venous thrombosis, atherosclerosis, stroke, and peripheral artery disease.

Indications for use Provides pre-therapeutic guidance for drug and dose selection. The thrombosis testing detects the two most common inherited thrombophilias: Prothrombin-related and Factor V Leiden-related.

Limitations Drug metabolism is also influenced by race, ethnicity, diet and other medications. All factors should be considered prior to initiating new therapy. Only the common gene variants are tested in this panel.

FDA Warning for Plavix. March 12, 2010 — FDA Announces New Boxed Warning on Plavix
Alerts patients, health care professionals to potential for reduced effectiveness The U.S. Food and Drug Administration has issued a black box warning against clopidogrel (Plavix) alerting patients and healthcare professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form. Plavix reduces the risk of heart attack, unstable angina, stroke, and cardiovascular death in patients with cardiovascular disease by making platelets less likely to form blood clots. Plavix does not have its anti-platelet effects until it is metabolized into its active form by the liver enzyme, CYP2C19. People who have reduced functioning of their CYP2C19 liver enzyme cannot effectively convert Plavix to its active form. As a result, Plavix may be less effective in altering platelet activity in those people. These “poor metabolizers” may not receive the full benefit of Plavix treatment and may remain at risk for heart attack, stroke, and cardiovascular death.